Literature DB >> 2110907

Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor.

W G Robison1, T N Tillis, N Laver, J H Kinoshita.   

Abstract

Recent evidence obtained from both galactosemic dogs and rats indicated that aldose reductase inhibitors could prevent several capillary lesions which were similar to those typical of diabetic retinopathy in humans. The present study demonstrates that diabetes-like histopathological changes in the intact retina, which were not visible in the vessel whole mounts used previously, can also be prevented. Sprague-Dawley rats were fed diets containing 50% galactose with or without an aldose reductase inhibitor (tolrestat). After 28 months of galactose feeding, the findings from retinal transections examined by light and electron microscopy were consistent with reports on vessel whole mounts, but showed several additional changes. There was a marked increase in the thickness of the retinal inner limiting membrane, as well as in the capillary basement membranes. There was extensive gliosis and disruption of retinal layers as well as pericyte degeneration, endothelial cell proliferation, accellularity, capillary dilation, and microaneurysm formation. The contents of pericyte compartments in the capillary wall were often replaced with non-pericyte cytoplasm, which appeared glial cell-like. Many of the lumens of acellular capillaries were occluded with debris from degenerating endothelial cells or with cytoplasm possibly originating from glial cell processes. Structures suggestive of degenerated microaneurysms were present mainly in the inner nuclear and outer plexiform layers. The microaneurysms and other major changes were limited to the central and paracentral retina. All these retinal lesions were prevented with orally administered tolrestat. Thus, long-term galactosemia in rats induced histopathologically visible angiopathies, simulating those occurring in background diabetic retinopathy in humans, and these were prevented by treatment with an aldose reductase inhibitor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110907     DOI: 10.1016/0014-4835(90)90136-i

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  15 in total

Review 1.  Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease.

Authors:  Joanna Kur; Eric A Newman; Tailoi Chan-Ling
Journal:  Prog Retin Eye Res       Date:  2012-05-03       Impact factor: 21.198

2.  Importance of sustained high glucose condition in the development of diabetic osteopenia: possible involvement of the polyol pathway.

Authors:  M Inaba; Y Nishizawa; A Shioi; H Morii
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Therapeutic Modalities in Diabetic Nephropathy: Future Approaches.

Authors:  William Brian Reeves; Bishal B Rawal; Emaad M Abdel-Rahman; Alaa S Awad
Journal:  Open J Nephrol       Date:  2012-06-25

4.  Polyol effects on growth factors and MAPK signaling in rat retinal capillary cells.

Authors:  Peng Zhang; Zifeng Zhang; Peter F Kador
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-20       Impact factor: 2.671

5.  The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy.

Authors:  A Tromp; J M Hooymans; B C Barendsen; J J van Doormaal
Journal:  Doc Ophthalmol       Date:  1991       Impact factor: 2.379

Review 6.  Metabolic syndrome and associated chronic kidney diseases: nutritional interventions.

Authors:  P Anil Kumar; P Swathi Chitra; G Bhanuprakash Reddy
Journal:  Rev Endocr Metab Disord       Date:  2013-09       Impact factor: 6.514

Review 7.  Retinal fibrosis in diabetic retinopathy.

Authors:  Sayon Roy; Shruti Amin; Sumon Roy
Journal:  Exp Eye Res       Date:  2016-01       Impact factor: 3.467

Review 8.  The role of polyols in the pathophysiology of hypergalactosemia.

Authors:  G T Berry
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

9.  The isolation and characterization of β-glucogallin as a novel aldose reductase inhibitor from Emblica officinalis.

Authors:  Muthenna Puppala; Jessica Ponder; Palla Suryanarayana; Geereddy Bhanuprakash Reddy; J Mark Petrash; Daniel V LaBarbera
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

10.  Deletion of aldose reductase from mice inhibits diabetes-induced retinal capillary degeneration and superoxide generation.

Authors:  Jie Tang; Yunpeng Du; J Mark Petrash; Nader Sheibani; Timothy S Kern
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.